Fatty acid amide hydrolase shapes NKT cell responses by influencing the serum transport of lipid antigen in mice

Journal of Clinical Investigation

Volumn 120, Issue 6, 2010, Pages 1873-1884

  Freigang, Stefan ^a   Zadorozhny, Victoria ^a   McKinney, Michele K ^a   Krebs, Philippe ^a   Herro, Rana ^a   Pawlak, Joanna ^a   Kain, Lisa ^a   Schrantz, Nicolas ^a   Masuda, Kim ^a   Liu, Yang ^b   Savage, Paul B ^b   Bendelac, Albert ^c,d   Cravatt, Benjamin F ^a   Teyton, Luc ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b N243 Eyring Science Center   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; ANTIGEN; CD1D ANTIGEN; FATTY ACID AMIDASE; GLYCOLIPID ANTIGEN; INTERFERON; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN PRESENTATION; ARTICLE; CELL FUNCTION; CELL INTERACTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; ENZYME ISOLATION; IMMUNE RESPONSE; IMMUNIZATION; IN VITRO STUDY; IN VIVO STUDY; LIPID TRANSPORT; LYMPHOCYTE PROLIFERATION; METASTASIS; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SPLEEN CELL; T LYMPHOCYTE ACTIVATION; THYMOCYTE;

ADJUVANTS, IMMUNOLOGIC; AMIDOHYDROLASES; ANIMALS; ANTIGENS; GALACTOSYLCERAMIDES; GLYCOLIPIDS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; NATURAL KILLER T-CELLS; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 77953181755     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI40451     Document Type: Article

References (55)

1. Brigl M, Brenner MB. CD1: antigen presentation and T cell function. Annu Rev Immunol. 2004;22:817-890. (Pubitemid 38680443)
2. Kronenberg M. Toward an understanding of NKT cell biology: progress and paradoxes. Annu Rev Immunol. 2005;23:877-900. (Pubitemid 40563188)
3. Bendelac A, Savage PB, Teyton L. The biology of NKT cells. Annu Rev Immunol. 2007;25:297-336.
4. Zhou D, et al. Editing of CD1d-bound lipid antigens by endosomal lipid transfer proteins. Science. 2004;303(5657):523-527. (Pubitemid 38120850)
5. Fischer K, et al. Mycobacterial phosphatidylinositol mannoside is a natural antigen for CD1drestricted T cells. Proc Natl Acad Sci U S A. 2004;101(29):10685-10690. (Pubitemid 38955803)
6. Kinjo Y, et al. Recognition of bacterial glycosphingolipids by natural killer T cells. Nature. 2005;434(7032):520-525. (Pubitemid 40477061)
7. Mattner J, et al. Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature. 2005;434(7032):525-529. (Pubitemid 40477062)
8. Kinjo Y, et al. Natural killer T cells recognize diacylglycerol antigens from pathogenic bacteria. Nat Immunol. 2006;7(9):978-986. (Pubitemid 44263912)
9. Fujii S, Liu K, Smith C, Bonito AJ, Steinman RM. The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation. J Exp Med. 2004;199(12):1607-1618. (Pubitemid 38821994)
10. Fujii S, Shimizu K, Hemmi H, Steinman RM. Innate Valpha14(+) natural killer T cells mature dendritic cells, leading to strong adaptive immunity. Immunol Rev. 2007;220:183-198. (Pubitemid 350045564)
11. Fujii S, Shimizu K, Smith C, Bonifaz L, Steinman RM. Activation of natural killer T cells by alphagalactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J Exp Med. 2003;198(2):267-279. (Pubitemid 36987852)
12. Hermans IF, et al. NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells. J Immunol. 2003;171(10):5140-5147.
13. Galli G, et al. Invariant NKT cells sustain specific B cell responses and memory. Proc Natl Acad Sci U S A. 2007;104(10):3984-3989. (Pubitemid 47181565)
14. Cui J, et al. Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors. Science. 1997;278(5343):1623-1626. (Pubitemid 27516281)
15. Smyth MJ, et al. Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med. 2000;191(4):661-668.
16. Giaccone G, et al. A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res. 2002;8(12):3702-3709.
17. Nieda M, et al. Therapeutic activation of Valpha24+Vbeta11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood. 2004;103(2):383-389.
18. Chang DH, et al. Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J Exp Med. 2005;201(9):1503-1517.
19. Ishikawa A, et al. A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent nonsmall cell lung cancer. Clin Cancer Res. 2005;11(5):1910-1917. (Pubitemid 40471857)
20. Terabe M, et al. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4RSTAT6 pathway. Nat Immunol. 2000;1(6):515-520.
21. Hayakawa Y, Takeda K, Yagita H, Van Kaer L, Saiki I, Okumura K. Differential regulation of Th1 and Th2 functions of NKT cells by CD28 and CD40 costimulatory pathways. J Immunol. 2001;166(10):6012-6018. (Pubitemid 32440726)
22. Miyamoto K, Miyake S, Yamamura T. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature. 2001;413(6855):531-534. (Pubitemid 32938752)
23. Gumperz JE, Miyake S, Yamamura T, Brenner MB. Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J Exp Med. 2002;195(5):625-636. (Pubitemid 34461507)
24. Crowe NY, et al. Differential antitumor immunity mediated by NKT cell subsets in vivo. J Exp Med. 2005;202(9):1279-1288.
25. van den Elzen P, et al. Apolipoprotein-mediated pathways of lipid antigen presentation. Nature. 2005;437(7060):906-910. (Pubitemid 41486768)
26. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature. 1996;384(6604):83-87.
27. McKinney MK, Cravatt BF. Structure and function of fatty acid amide hydrolase. Annu Rev Biochem. 2005;74:411-432.
28. Patricelli MP, Lashuel HA, Giang DK, Kelly JW, Cravatt BF. Comparative characterization of a wild type and transmembrane domain-deleted fatty acid amide hydrolase: identification of the transmembrane domain as a site for oligomerization. Biochemistry. 1998;37(43):15177-15187.
29. Bracey MH, Hanson MA, Masuda KR, Stevens RC, Cravatt BF. Structural adaptations in a membrane enzyme that terminates endocannabinoid signaling. Science. 2002;298(5599):1793-1796.
30. Cravatt BF, et al. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci U S A. 2001;98(16):9371-9376. (Pubitemid 32743923)
31. Massa F, et al. The endogenous cannabinoid system protects against colonic inflammation. J Clin Invest. 2004;113(8):1202-1209. (Pubitemid 38544105)
32. Karsak M, et al. Attenuation of allergic contact dermatitis through the endocannabinoid system. Science. 2007;316(5830):1494-1497. (Pubitemid 46906619)
33. Lichtman AH, Shelton CC, Advani T, Cravatt BF. Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia. Pain. 2004;109(3):319-327. (Pubitemid 38638709)
34. Cravatt BF, Saghatelian A, Hawkins EG, Clement AB, Bracey MH, Lichtman AH. Functional disassociation of the central and peripheral fatty acid amide signaling systems. Proc Natl Acad Sci U S A. 2004;101(29):10821-10826. (Pubitemid 38955826)
35. Kawano T, et al. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science. 1997;278(5343):1626-1629. (Pubitemid 27516282)
36. Edwards JL, Apicella MA. The role of lipooligosaccharide in Neisseria gonorrhoeae pathogenesis of cervical epithelia: lipid A serves as a C3 acceptor molecule. Cell Microbiol. 2002;4(9):585-598.
37. Alexander JP, Cravatt BF. Mechanism of carbamate inactivation of FAAH: implications for the design of covalent inhibitors and in vivo functional probes for enzymes. Chem Biol. 2005;12(11):1179-1187.
38. Felder CC, et al. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol. 1995;48(3):443-450.
39. Wacnik PW, Luhr KM, Hill RH, Ljunggren HG, Kristensson K, Svensson M. Cannabinoids affect dendritic cell (DC) potassium channel function and modulate DC T cell stimulatory capacity. J Immunol. 2008;181(5):3057-3066.
40. Prigozy TI, et al. Glycolipid antigen processing for presentation by CD1d molecules. Science. 2001;291(5504):664-667.
41. Liu Y, et al. A modified alpha-galactosyl ceramide for staining and stimulating natural killer T cells. J Immunol Methods. 2006;312(1-2):34-39. (Pubitemid 43795980)
42. Zajonc DM, et al. Structure and function of a potent agonist for the semi-invariant natural killer T cell receptor. Nat Immunol. 2005;6(8):810-818. (Pubitemid 43090467)
43. Pope C, et al. Organ-specific regulation of the CD8 T cell response to Listeria monocytogenes infection. J Immunol. 2001;166(5):3402-3409. (Pubitemid 33117342)
44. Jack RS, et al. Lipopolysaccharide-binding protein is required to combat a murine gram-negative bacterial infection. Nature. 1997;389(6652):742-745.
45. Wurfel MM, Kunitake ST, Lichenstein H, Kane JP, Wright SD. Lipopolysaccharide (LPS)-binding protein is carried on lipoproteins and acts as a cofactor in the neutralization of LPS. J Exp Med. 1994;180(3):1025-1035. (Pubitemid 24256615)
46. Anderson NL, et al. The human plasma proteome: a nonredundant list developed by combination of four separate sources. Mol Cell Proteomics. 2004;3(4):311-326.
47. Hood BL, et al. Investigation of the mouse serum proteome. J Proteome Res. 2005;4(5):1561-1568.
48. Karava V, Fasia L, Siafaka-Kapadai A. Anandamide amidohydrolase activity, released in the medium by Tetrahymena pyriformis. Identification and partial characterization. FEBS Lett. 2001;508(3):327-331. (Pubitemid 33135464)
49. Karava V, et al. Anandamide metabolism by Tetrahymena pyriformis in vitro. Characterization and identification of a 66 kDa fatty acid amidohydrolase. Biochimie. 2005;87(11):967-974.
50. Smyth MJ, et al. Sequential production of interferon- gamma by NK1.1(+) T cells and natural killer cells is essential for the antimetastatic effect of alpha-galactosylceramide. Blood. 2002; 99(4):1259-1266.
51. Sasakawa A, et al. Activated liver dendritic cells generate strong acquired immunity in alphagalactosylceramide treatment. J Hepatol. 2009;50(6):1155-1162.
52. Park SH, Roark JH, Bendelac A. Tissue-specific recognition of mouse CD1 molecules. J Immunol. 1998;160(7):3128-3134. (Pubitemid 28164700)
53. Inaba K, et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med. 1992;176(6):1693-1702.
54. Saghatelian A, McKinney MK, Bandell M, Patapoutian A, Cravatt BF. A FAAH-regulated class of N-acyl taurines that activates TRP ion channels. Biochemistry. 2006;45(30):9007-9015. (Pubitemid 44156362)
55. Cantu C 3rd, Benlagha K, Savage PB, Bendelac A, Teyton L. The paradox of immune molecular recognition of alpha-galactosylceramide: low affinity, low specificity for CD1d, high affinity for alpha beta TCRs. J Immunol. 2003;170(9):4673-4682. (Pubitemid 36519974)